Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eleven brokerages that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month […]